TipRanks
Advertisement
Advertisement

DE:UP0 Stock Latest News

Ultragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target
RatingsUltragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target
12d ago
RARE
Ultragenyx call volume above normal and directionally bullish
PremiumThe Fly
Ultragenyx call volume above normal and directionally bullish
13d ago
RARE
Ultragenyx price target raised to $18 from $16 at Evercore ISI
PremiumThe Fly
Ultragenyx price target raised to $18 from $16 at Evercore ISI
16d ago
RARE
Ultragenyx price target raised to $35 from $32 at Barclays
PremiumThe Fly
Ultragenyx price target raised to $35 from $32 at Barclays
16d ago
RARE
Ultragenyx price target raised to $20 from $18 at Morgan Stanley
PremiumThe Fly
Ultragenyx price target raised to $20 from $18 at Morgan Stanley
18d ago
RARE
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
PremiumThe FlyAbeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
19d ago
ABEO
RARE
Ultragenyx price target raised to $39 from $37 at Canaccord
Premium
The Fly
Ultragenyx price target raised to $39 from $37 at Canaccord
19d ago
RARE
Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald
Premium
The Fly
Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald
19d ago
RARE
Ultragenyx price target raised to $32 from $31 at Citi
PremiumThe Fly
Ultragenyx price target raised to $32 from $31 at Citi
19d ago
RARE
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
PremiumRatings
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
19d ago
RARE
Ultragenyx wins FDA approval for FAYUVI gene therapy
PremiumCompany Announcements
Ultragenyx wins FDA approval for FAYUVI gene therapy
19d ago
8K
RARE
Ultragenyx confirms FDA approval of Fayuvi
PremiumThe Fly
Ultragenyx confirms FDA approval of Fayuvi
19d ago
RARE
FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
PremiumThe FlyFDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
19d ago
RARE
Ultragenyx call volume above normal and directionally bullish
Premium
The Fly
Ultragenyx call volume above normal and directionally bullish
20d ago
RARE
Ultragenyx treatment of GNE myopathy granted orphan designation
Premium
The Fly
Ultragenyx treatment of GNE myopathy granted orphan designation
22d ago
RARE
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
26d ago
GS
MS
Ultragenyx price target lowered to $32 from $43 at Barclays
PremiumThe Fly
Ultragenyx price target lowered to $32 from $43 at Barclays
1M ago
RARE
Ultragenyx downgraded at Morgan Stanley after Angelman study fails
PremiumThe Fly
Ultragenyx downgraded at Morgan Stanley after Angelman study fails
1M ago
RARE
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe Fly
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
1M ago
RARE
Ultragenyx falls -44.0%
PremiumThe FlyUltragenyx falls -44.0%
1M ago
RARE
Midday Fly By: Nvidia to acquire Hugging Face, Broadcom reports Q3 beat
Premium
The Fly
Midday Fly By: Nvidia to acquire Hugging Face, Broadcom reports Q3 beat
1M ago
BA
LE
Ultragenyx falls -44.6%
Premium
The Fly
Ultragenyx falls -44.6%
1M ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >